Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Feb 24, 2020 (7 years ago)

Zoledronic Acid Injection 5 mg/100 mL

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL), Solution for Intravenous Infusion, Sterile Solution, 100 mL Single - Dose Vial per Carton, Rx Only, Distributed by: Breckenridge Pharmaceutical, Inc., Boca Raton, FL 33487, Manufactured by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 51991-064-98.

Affected NDC 51991-0064-98

Compare with the code on your package — it is the most precise check available.

Drug: Zoledronic

Recalling firm
Breckenridge Pharmaceutical, Inc
NDC code
51991-064-98
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1063-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zoledronic recalls

See all
Class II · Moderate risk

Zoledronic Acid Injection

Lack of Assurance of Sterility; defective seals where the metal silver ring was not attached tightly to the vial

Terminated Sterility / contamination Dr. Reddy's Laboratories, Inc. NDC 55111-688-52 D-0784-2016
Class II · Moderate risk

Zoledronic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-958-2015

Other recalls by Breckenridge Pharmaceutical, Inc

All 2020 recalls